Stories from Basel · Switzerland

Novo Nordisk shares fell 2.9% in morning trading following news regarding competition for its flagship heart disease medication. The decline follows developments involving an Alphabet subsidiary and the US Department of Defense. The company's patent for the medication is reportedly expiring. The decline follows the introduction of a generic competitor to the Swiss pharmaceutical group's flagship heart disease medication.

Mark Vogelschef, a physician at University Clinics in Basel, reported that nitazines have been found mixed into medications like Xanax. These substances may be added intentionally to increase dependency or as a result of unregulated laboratory processes. The drugs are often ordered via the internet without proper precautions. It noted that laboratories might intentionally mix these substances to increase dependency, though this remains unconfirmed.

FC Basel has successfully built up equity, a strategy that could be. The club did not invest all Champions League earnings into wage costs, which are the largest expense. Wage costs should not exceed 70 percent of revenue to avoid problems. Building equity provides a buffer for difficult times.

The city of Basel has established a 6 million Swiss franc 'City Revitalization Fund' to maintain the attractiveness of the downtown area. The project aims to stimulate local activity and support urban development initiatives within the city center. Funding is intended to be utilized within a specific timeframe to ensure economic impact.